EVE Health Group (ASX: EVE) has entered into a telehealth services agreement with Australian provider hubMed to enhance the safety, quality, and continuity of care for patients using EVE’s ++therapeutic products++ including ++Dyspro++ for dysmenorrhoea and ++Libbo++ for erectile dysfunction.
The agreement will have an initial term of 12 months, and EVE will pay a monthly service fee to hubMed based on the number of patient support interactions delivered during each period.
There are no upfront fees, fixed charges, guaranteed volumes, or minimum number of interactions required.
Continuity of Care
Improving continuity of care is critical in the areas of women’s and men’s health, where conditions are often under-diagnosed and under-managed and patients require structured follow-up to support adherence to clinical guidance in a timely manner.
EVE expects the hubMed program to offer patients regular touch points with registered nurses who can reinforce safe usage of EVE’s products, highlight triage concerns within scope, and communicate with the patient’s usual treating practitioner when clinically necessary.
Chief executive officer Damian Wood said the new agreement would support better real-world outcomes and complement the care provided through traditional medical channels.
Oft-Overlooked Conditions
“Women’s and men’s health conditions are often overlooked and patients can benefit greatly from reliable follow-up and trusted clinical support—this partnership strengthens our ability to provide that support,” Mr Wood said.
“hubMed has a strong clinical governance framework and a model that helps patients stay informed, confident, and connected to their treating practitioners, which is an important step in delivering better outcomes for those who are prescribed our therapies.”
“Our registered nurses have significant experience supporting patients in areas where continuity of care is especially important and we are pleased to partner with EVE on a program that prioritises patient well-being, safety, and communication with prescribers,” hubMed managing director Jessica Stewart said.
“This model will help ensure that patients feel supported throughout their treatment journey.”
Stigmas and Burdens
Libbo offers a modern dosage form that may support better adherence and patient acceptance of erectile dysfunction, which affects one in five men over the age of 18 years and up to 40% of men over 40 years.
The condition can impact well-being, confidence and relationships, yet remains under-treated due to stigma, delays in seeking help and inconsistent medical follow-up.
Dyspro has been developed to address a significant unmet need in dysmenorrhoea – disruptive menstrual symptoms – under the supervision of authorised prescribers.
A recent Australian study found that 77% of women of reproductive age experience dysmenorrhoea, with almost half reporting missed days of work or study.
The economic burden of menstrual symptoms in Australia is estimated at approximately $14.2 billion per year, while the annual cost per woman with chronic pelvic pain can exceed $24,000.
Community Platform Launch
As part of the Dyspro launch, EVE has introduced the Reclaim My Cycle ++online community and education platform++ to empower women in managing their dysmenorrhoea and endometriosis symptoms.
The platform combines patient-friendly education and materials to support awareness, engagement and informed clinical conversations.
EVE is working on a similar platform to support men’s health as part of the upcoming Libbo launch.
“Our expanded digital ecosystem is designed to create consistent, evidence-informed support across women’s and men’s health and strengthen the overall launch pathway for our therapeutic products,” Mr Wood said.
